The DEA banned a drug some opioid users called a miracle
By Manisha Krishnan, wired.com · Nov 4, 2026, 9:08 AM CST
In 2012, as the driver of deaths in the opioid crisis began moving from prescription pills to heroin, Laura Bohn was tasked with finding safer drugs to manage pain. Funded by the National Institute on Drug Abuse, in 2017 she and other scientists revealed in the science journal Cell that several compounds—including a particularly promising one called SR-17018—could relieve pain in mice without caus
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisSensationalismThe headline frames the scientific finding as a dramatic ban, creating a sense of urgency and drama without evidence.
Appeal to HopeThe article emphasizes the potential of the compound to solve a major problem in the opioid crisis, appealing to readers' desire for a breakthrough.
Authority AppealCiting federal funding is used to lend credibility to the research.
OmissionThe article truncates before providing details on the study methodology or any discussion of limitations, leaving readers without full context.
Context
AI analysisMissing context
The article does not provide any information about a DEA ban, including when it occurred, the legal basis, or official statements from the DEA. It also lacks context about whether SR‑17018 has been tested in humans, its regulatory status, or any subsequent research.
Important context
The findings are limited to pre‑clinical mouse studies; efficacy and safety in humans remain unproven. Funding by a federal agency (NIDA) does not imply regulatory approval. Patent filing does not equate to market availability.
Opinion vs. reporting
AI analysisThe piece mixes reporting of scientific results with a sensational headline that implies regulatory action not supported by the text, blurring the line between factual reporting and opinion.